Australian (ASX) Stock Market Forum

WFL - Wellfully Limited

Jump to new
condog said:
I agree vulture, but OBJ was loaded up to the hilt with short term traders, any change that delays timeline causes them to exit rapidly.

In actual fact its the 2nd best result OBJ could have wanted and was already priced in imo.

The best result would be a full commercial venture, but its a bit premature for that, so this in reality shows great confidence in OBJ transdermal patch. Given 3M simultaneously have attempted to employ an entire transdermal division things still look very promising for 3M, i actually dumped mine near the low today. More of a capital protection measure. I think they will test new lows again before some common sense prevails. Its only opinion so DYOR.

I will probably re enter towards the end of this trial.
Click to expand...

I was very fortunate to get out at .043c after a skim read of the announcement, came to the part which said 6 month extension and was out not much later, a lot of churning and burning in the five minutes that followed. I agree it will come back, they seem to slip an announcement out every so often to keep things lively.
 
Putty7 said:
I was very fortunate to get out at .043c after a skim read of the announcement, came to the part which said 6 month extension and was out not much later, a lot of churning and burning in the five minutes that followed. I agree it will come back, they seem to slip an announcement out every so often to keep things lively.
Click to expand...

I done the opposite, and have used the dip to load up. I realise it will be a while before the market starts to retract back up. But I have an feeling we maybe seeing a takeover or partnership with some fairly large players.

I think the 6 months is just to buy sometime. I have no doubt that 3M has done it's research.

Anyone else have similar thoughts.
 
Yes, very similar thoughts here. 3M has no need to string this out, if they didn't think it could be a commercial success they would've left long ago, but requesting a second extension? To me that says loads about this deal, but this stock is riddled with day/short term traders who don't have the patience to wait 6 months.

The good news is they'll be happy to buy in at twice this price leading into the annoucement, and who knows what else will happen before then. Having said that I'll be waiting to see ~3c or possibly high 2's before accumulating, unfortunately I think it still has further to fall.
 
why is no 1 talking about OBJ the 3m ann is due out soon and it is trading down even with the cpl of big buys lately any1 got any ideas
 
Word is that OBJ will be issuing a quarterly progress statement about all its partnering activities by the end of this month.

Which is NOT the stellar 3M ann we were all hoping for....hence today's sell off.

Nothing to worry about long term though. Just the short term-ers going elsewhere. Support at 2c might be the place to buy imo
 
Got some OBJ and put stop $0.018

And I almost know that if it drops like stone, I'll be out sooner.
(My interpretation of Nick's take on general mood of the market)
 
Lot of activity today & a 60% hike in sp...

>>>>>
OBJ Limited (ASX: OBJ) is pleased to announce that GlaxoSmithKline Consumer Healthcare (GSK) has informed the Company of its desire to proceed with an FIMTM development program in a major consumer healthcare sector following a sequence of successful technology evaluations. The target application for the FIMTM development is a key sector in consumer healthcare.

GlaxoSmithKline Consumer Healthcare has issued the following statement.
“GlaxoSmithKline Consumer Healthcare (GSK) has reported statistically significant levels of enhancement in an in vitro testing model by the OBJ technology in a global Consumer Healthcare application. These results are the outcomes of the short term evaluation agreement with GSK announced to shareholders on 18th February 2010.
GSK and OBJ are now in discussions regarding the next steps of this program which will include a technology integration program and in vivo human efficacy testing to quantify the business opportunity"

Background to the Announcement:
GSK and OBJ have collaborated in consumer healthcare applications since 2006 and the current discussions for the establishment of a major FIMTM product development program are the next steps in one of those programs.

The Consumer Healthcare program under discussion will include a design and development stage to build OBJ's FIMTM technology into a common household consumer product. These will then be used in human efficacy studies to demonstrate the level of consumer benefit provided by the FIMTM technology and consumer acceptance testing to determine marketability within the US$29 billion market sector. These programs will be used to quantify the size of the potential international market and to determine the resources necessary to exploit the commercial opportunity.
>>>>>

Been a lot of hype with this stock with the speculator back in 09 & early 10, this feasibility study sounds a pretty big deal- anyone any thoughts??
 
buffalo66 said:
Lot of activity today & a 60% hike in sp...

>>>>>
OBJ Limited (ASX: OBJ) is pleased to announce that GlaxoSmithKline Consumer Healthcare (GSK) has informed the Company of its desire to proceed with an FIMTM development program in a major consumer healthcare sector following a sequence of successful technology evaluations. The target application for the FIMTM development is a key sector in consumer healthcare.

GlaxoSmithKline Consumer Healthcare has issued the following statement.
“GlaxoSmithKline Consumer Healthcare (GSK) has reported statistically significant levels of enhancement in an in vitro testing model by the OBJ technology in a global Consumer Healthcare application. These results are the outcomes of the short term evaluation agreement with GSK announced to shareholders on 18th February 2010.
GSK and OBJ are now in discussions regarding the next steps of this program which will include a technology integration program and in vivo human efficacy testing to quantify the business opportunity"

Background to the Announcement:
GSK and OBJ have collaborated in consumer healthcare applications since 2006 and the current discussions for the establishment of a major FIMTM product development program are the next steps in one of those programs.

The Consumer Healthcare program under discussion will include a design and development stage to build OBJ's FIMTM technology into a common household consumer product. These will then be used in human efficacy studies to demonstrate the level of consumer benefit provided by the FIMTM technology and consumer acceptance testing to determine marketability within the US$29 billion market sector. These programs will be used to quantify the size of the potential international market and to determine the resources necessary to exploit the commercial opportunity.
>>>>>

Been a lot of hype with this stock with the speculator back in 09 & early 10, this feasibility study sounds a pretty big deal- anyone any thoughts??
Click to expand...

Buffalo66, this week on Sky Business Channel an analyst from TMS Capital Ben (??) reckoned he owned some of these shares personally, to my (simple) mind he comes across as a pretty smart chap. Ever since I saw the program I've been researching them a bit and I don't mind what I see. As a result have dipped my toe into OBJ and OBJO.

Whilst I'm not in the habit of mentioning other share forums (or know anything about this particular industry except that it is very high risk) there are a couple of dudes (on another forum) that are well worth a read. They go by; surges and abdm and appear well versed in this bio-spec space.

boronia
 
Stop moved to $0.024 as it looks like latest short term support.

I didn't even know it is Bio Tech Co
Too late now to worry about what they do, must concentrate on what I have to do.
 
wish I had listened to my own advice (back a couple of posts) and bought more when it bounced off 2.0c (it then went to 3.8c when that ann suprised everyone). doh!

I was stuck back up at 3.0c though so I was glad to get out when it went back up. It subsequently settled back down to and bounced off support at 2.5c

People are buying up now ahead of the agm I hear. A 1-for-1 oppie offer is on the table but they haven't announced the record date.

If it goes through there could be a big sell off after the allotment yeah?
 
ubtheboss said:
wish I had listened to my own advice (back a couple of posts) and bought more when it bounced off 2.0c (it then went to 3.8c when that ann suprised everyone). doh!

I was stuck back up at 3.0c though so I was glad to get out when it went back up. It subsequently settled back down to and bounced off support at 2.5c

People are buying up now ahead of the agm I hear. A 1-for-1 oppie offer is on the table but they haven't announced the record date.

If it goes through there could be a big sell off after the allotment yeah?
Click to expand...

I think that the oppy offer is not a 1-for-1 offer but merely an extension of the existing Dec 2010 options expiry date to Dec 2011. My understanding is that under current ASX rules you can't just 'extend' an options expiry date so what OBJ are doing is offering existing oppy holders, for a very small amount, the opportunity to do this. This will be voted upon at the AGM on the 20(?) Dec.
 
I think OBJ's AGM was today did anyone from ASF attend? If so, their thoughts? So far I have only spoken to one person whom said he chatted with Glyn and found it all very positive looking into the future.
 
OBJ forms part of my long term speculative portfolio.

Today they all but announced the granting of the US patent for their Dermaportation technology.

This is an important step in securing a partnet agreement. Quite simply no company would sign a licencing agreement without "protection". If they were to launch a product utilising the technology it would be too easy for it to be replicated and their marketing advantage lost.

I also think many traders/investors will overlook the importance of this announcement and take this opportunity to exit (SP came off a low of 1.6c today to an intraday high of 2.0) given the relatively weak performance of OBJ over the past few weeks.

http://asx.com.au/asxpdf/20110823/pdf/420km7lqdnrlv0.pdf

Looking forward to any other holders thoughts.
 
Hi investorpaul,

I think you probably already know my thoughts, as I do yours. I'm not sure how to manage video links on this site however the following, although a rather rough video clip from back in 2006 at the 34th Cancer Convention sums up the future of PEMF technology. As the speaker tells his audience, "There are two ways moving forward in medicine, and you'll be hearing a lot more about this."

"The first is Stem Cell Therapy"
"The second is Pulsed Electrmagnetic Fields"

http://www.youtube.com/watch?v=g1GazHbamd0&feature=related
___

A couple more recent links of interest:

Magnetic Hair Fibers
http://www.elerman.com/page.asp?pageID=265
http://www.cosmeticsdesign.com/Form...ight&utm_medium=OnSite&utm_campaign=copyright
___

Electromagnetic Fields for Cellulite reduction
http://www.youtube.com/watch?v=8JJkn1eWNhY&feature=related
___

http://clinicaltrials.gov/ct2/show/NCT01255631?term=NCT01255631&rank=1

“Pulsed electromagnetic fields (PEMF) have been shown to be effective in the treatment of fractures and spinal fusion, relief of pain in acute sprains and whiplash injuries, improvement of skin blood flow, healing of venous stasis ulcers, and reduction of postmastectomy lymphedema. Indeed, radiofrequency PEMF devices are FDA approved for pain and edema relief. PEMF devices are economical and disposable, and can be incorporated unobtrusively in standard post-op dressings. We have recently reported, in a double-blind, placebo-controlled study on breast reduction, that post-op PEMF therapy produced a significant decrease in pain and pain medication use, along with a concomitant decrease in IL1-beta in the wound bed.1 The current pilot study will be designed to determine if PEMF treatment, given in addition to standard of care, can reduce post-operative discomfort and morbidity after lumpectomy and SLND, or lumpectomy and ALND. Lumpectomy and ALND/SLND patients enrolled in the double-blind, placebo-controlled study will undergo standard surgery, but will be randomized to one of two groups: the treatment group with a PEMF coil placed around the arm and the control group with a coil that delivers no PMF. We expect postoperative pain to be reduced in the PEMF-treated patients as well as improved arm mobility and strength. The use of PEMF might reduce the need for narcotic pain medications and their side effects of sedation, nausea, and vomiting. It may also reduce costs related to arm morbidity.”

It would appear that the FDA is already very supportive of PEMF technology and from I’ve been reading on their website more recently they have been conducting many workshops in order to fast track new innovative delivery device technologies.

November is looking to be a very good month imo ;)
 
Huge volume on Friday caught my attention in one of my scans. This will be interesting to monitor to see if anything happens.

OBJ.png
 
Regretting not getting in this one!!

I was looking for an entry at 0.017 with a stop at 0.015. This would already be quite nice profit at .022.

I really like these sort of setups. I've seen some enormous returns on some in the past. I don't know what the future holds for OBJ though. We'll see.
 

Similar threads

Y
HZL - HZ Lim
Replies
2
Views
5K
greggles
greggles
Y
UNX - Uranex Limited
2 3
Replies
59
Views
17K
Tyler Durden
Tyler Durden
Y
AEV - Avenira Limited
52 53 54
Replies
1K
Views
187K
frugal.rock
frugal.rock
Y
CT1 - Constellation Technologies
Replies
13
Views
8K
Trav.
Trav.
Top